Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Hematology

Standard of Care Treatment for AL Amyloidosis

At a Glance

The standard frontline treatment for AL amyloidosis is the Dara-CyBorD drug regimen, designed to rapidly stop the production of toxic light chains and allow organs to heal. Some eligible patients may also undergo an autologous stem cell transplant to help achieve long-term remission.

The treatment of AL amyloidosis has two main goals: first, to stop the production of toxic light chains quickly, and second, to give your organs a chance to heal [1][2]. Because the light chains themselves are toxic to your heart and kidneys, speed is of the essence in the first few months of care [3][4].

The “Dara-CyBorD” Standard

For most newly diagnosed patients, the standard frontline treatment is a combination therapy known as Dara-CyBorD [5][1]. This regimen was established by the landmark ANDROMEDA trial, which showed that adding the targeted drug Daratumumab to a standard chemotherapy backbone significantly improved how many patients achieved deep remission [5][6].

The regimen consists of four drugs given in repeated phases called “cycles” (usually lasting about 4 weeks each). A typical initial treatment phase (induction) lasts for 4 to 6 cycles:

  • Daratumumab: A targeted monoclonal antibody that kills abnormal plasma cells [5].
  • Cyclophosphamide: A traditional chemotherapy drug.
  • Bortezomib: A proteasome inhibitor that destroys “stressed” plasma cells. Important: Bortezomib can cause peripheral neuropathy (tingling or numbness in the hands and feet). Because amyloidosis itself can cause neuropathy, you must report any new numbness immediately so your doctor can adjust the dose.
  • Dexamethasone: A steroid used to treat the disease and prevent allergic reactions. Important: Dexamethasone can cause significant fluid retention. Since fluid overload is already a symptom of amyloid heart or kidney involvement, it is vital to know that steroids might temporarily worsen swelling, so you do not panic thinking the disease is progressing.

Defining Success: The VGPR Goal

In AL amyloidosis, your “response” to treatment is measured by how much the level of toxic light chains in your blood drops. Your doctor will look for a Very Good Partial Response (VGPR) or better [7][8].

  • VGPR: Your toxic light chain level (dFLC) has dropped to below 40 mg/L (or in some definitions, below 10 mg/L) [9][10].
  • Complete Response (CR): The abnormal protein is no longer detectable in your blood or urine [11][12].

Achieving a VGPR or CR within the first 1 to 3 months is the best predictor of long-term organ recovery and survival [3][13].

The Role of Stem Cell Transplant

Autologous Stem Cell Transplantation (ASCT) is a procedure where your own healthy stem cells are collected, high-dose chemotherapy is given to “reset” the bone marrow, and the stem cells are then returned to your body [14][15].

While ASCT used to be the primary goal for every patient, the success of Dara-CyBorD has made the timing of transplant a more nuanced decision. Some centers may recommend a transplant as part of the initial therapy for strong candidates, while others prefer to hold it in reserve for patients who do not achieve a deep enough response (like a CR) with Dara-CyBorD alone [16][17][18].

Who is “Eligible” for Transplant?
Eligibility is strict because the procedure requires robust organ function. Notably, doctors do not rely solely on “ejection fraction” (a common measure of how well the heart pumps). AL amyloidosis causes stiffening of the heart walls, meaning a patient can have a completely “normal” ejection fraction but still have severe heart failure that would make a transplant unsafe. Instead, eligibility is based on [19][20]:

  • Heart Function: Compensated heart failure (e.g., NYHA Class I or II), and a lack of recurrent syncope (fainting) or severe arrhythmias.
  • Mayo Stage: Patients in Stage I or II are generally the best candidates; Stage IIIb is often a contraindication [21].
  • Overall Health: Good kidney function and a strong “performance status” (ability to perform daily tasks).

Maintenance Therapy

After your initial treatment (induction), your doctor may recommend maintenance therapy [22]. This typically involves continuing Daratumumab as a single drug for several months or years to ensure the abnormal plasma cells do not return [23][16]. This long-term “suppression” is a key part of maintaining your organ health [24].

Common questions in this guide

What is the standard first-line treatment for AL amyloidosis?
For most newly diagnosed patients, the standard frontline treatment is a combination therapy called Dara-CyBorD. This includes the targeted drug Daratumumab along with three other medications designed to quickly stop the production of toxic light chains.
How do doctors measure if my AL amyloidosis treatment is working?
Doctors track the level of toxic light chains in your blood to measure your response to therapy. They aim for a Very Good Partial Response (VGPR) or Complete Response (CR), meaning light chain levels have dropped significantly or are no longer detectable.
Am I eligible for a stem cell transplant for AL amyloidosis?
Eligibility requires robust organ function, particularly in your heart and kidneys. Patients with well-compensated heart failure, good kidney function, Mayo Stage I or II disease, and a strong ability to perform daily tasks are generally the best candidates.
Can AL amyloidosis treatments cause swelling or fluid retention?
Yes, dexamethasone, a steroid used in the standard treatment regimen, can cause significant fluid retention. Because fluid overload is also a symptom of amyloid heart or kidney involvement, it is important to communicate any new swelling to your doctor immediately.
What is maintenance therapy for AL amyloidosis?
Maintenance therapy is used after your initial induction treatment to ensure abnormal plasma cells do not return. It typically involves continuing a targeted drug like Daratumumab alone for several months or years to protect your long-term organ health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for the Dara-CyBorD regimen, and how many cycles are we planning for the initial induction phase?
  2. 2.Are there any dose modifications to my treatment plan based on my heart or kidney function?
  3. 3.How will we measure my 'hematologic response' to ensure I am achieving a Very Good Partial Response (VGPR)?
  4. 4.Given my specific heart function and overall health, am I being considered for a stem cell transplant, and if so, when?
  5. 5.What is the plan for 'maintenance therapy' once my initial induction treatment is finished?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Daratumumab in AL amyloidosis.

    Wechalekar AD, Sanchorawala V

    Blood 2022; (140(22)):2317-2322 doi:10.1182/blood.2021014613.

    PMID: 35507692
  2. 2

    Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.

    Muchtar E, Dispenzieri A, Gertz MA, et al.

    Mayo Clinic proceedings 2021; (96(6)):1546-1577 doi:10.1016/j.mayocp.2021.03.012.

    PMID: 34088417
  3. 3

    Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era.

    Bazarbachi AH, Zanwar S, Hegenbart U, et al.

    HemaSphere 2025; (9(12)):e70276 doi:10.1002/hem3.70276.

    PMID: 41473002
  4. 4

    Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.

    Hu H, Wang Y, Xu M

    Pharmaceutical research 2025; doi:10.1007/s11095-025-03965-6.

    PMID: 41291170
  5. 5

    Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.

    Blair HA

    Drugs 2022; (82(6)):683-690 doi:10.1007/s40265-022-01705-3.

    PMID: 35416593
  6. 6

    Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.

    Oubari S, Hegenbart U, Schoder R, et al.

    Haematologica 2024; (109(1)):220-230 doi:10.3324/haematol.2023.283325.

    PMID: 37439344
  7. 7

    A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.

    Roussel M, Merlini G, Chevret S, et al.

    Blood 2020; (135(18)):1531-1540 doi:10.1182/blood.2019004369.

    PMID: 32108228
  8. 8

    Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.

    Kastritis E, Misra A, Gurskyte L, et al.

    Hematology (Amsterdam, Netherlands) 2023; (28(1)):2157581 doi:10.1080/16078454.2022.2157581.

    PMID: 36607151
  9. 9

    NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSIS.

    Idowu A, Tung L, Chu C, et al.

    European journal of case reports in internal medicine 2023; (10(2)):003768 doi:10.12890/2023_003768.

    PMID: 36970162
  10. 10

    Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner's perspective.

    Bomsztyk J, Khwaja J, Wechalekar AD

    Expert review of hematology 2022; (15(9)):781-788 doi:10.1080/17474086.2022.2115353.

    PMID: 36039749
  11. 11

    Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.

    Muchtar E, Gertz MA, Lacy MQ, et al.

    American journal of hematology 2020; (95(11)):1280-1287 doi:10.1002/ajh.25940.

    PMID: 32681737
  12. 12

    Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.

    Milani P, Basset M, Nuvolone M, et al.

    Blood cancer journal 2020; (10(8)):90 doi:10.1038/s41408-020-00355-6.

    PMID: 32873771
  13. 13

    Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.

    Ravichandran S, Cohen OC, Law S, et al.

    Blood cancer journal 2021; (11(6)):118 doi:10.1038/s41408-021-00510-7.

    PMID: 34155191
  14. 14

    Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.

    Sidiqi MH, Aljama MA, Buadi FK, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(13)):1323-1329 doi:10.1200/JCO.2017.76.9554.

    PMID: 29558277
  15. 15

    Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.

    Kim HR, Yoon SE, Kim D, et al.

    Clinical lymphoma, myeloma & leukemia 2023; (23(2)):97-103 doi:10.1016/j.clml.2022.10.010.

    PMID: 36464620
  16. 16

    Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.

    Yohannan B, Rees M, Gertz MA, et al.

    Blood neoplasia 2025; (2(2)):100092 doi:10.1016/j.bneo.2025.100092.

    PMID: 40453144
  17. 17

    Diagnosis and Treatment of AL Amyloidosis.

    Palladini G, Milani P

    Drugs 2023; (83(3)):203-216 doi:10.1007/s40265-022-01830-z.

    PMID: 36652193
  18. 18

    From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis.

    Muchtar E, Dispenzieri A, Buadi FK, et al.

    Blood advances 2025; (9(16)):4311-4316 doi:10.1182/bloodadvances.2025016586.

    PMID: 40590881
  19. 19

    Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

    Fuchida SI, Kawamura K, Sunami K, et al.

    Transplantation and cellular therapy 2022; (28(2)):76-82 doi:10.1016/j.jtct.2021.10.021.

    PMID: 34774818
  20. 20

    The Role of Autologous Stem Cell Transplantation in Amyloidosis.

    Vaxman I, Dispenzieri A

    Oncology (Williston Park, N.Y.) 2021; (35(8)):471-478 doi:10.46883/ONC.2021.3508.0471.

    PMID: 34398591
  21. 21

    Clinical characteristics and prognosis of a Chinese cohort with systemic light chain amyloidosis: a single-center study.

    Xie W, Wang Q, Zhou F, et al.

    International journal of hematology 2023; (118(2)):231-241 doi:10.1007/s12185-023-03617-8.

    PMID: 37247070
  22. 22

    Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.

    Wang Y, Xu P, Chen Y, et al.

    Molecular and clinical oncology 2016; (4(1)):107-113 doi:10.3892/mco.2015.658.

    PMID: 26870367
  23. 23

    Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.

    Yimer H, Melear J, Faber E, et al.

    Leukemia & lymphoma 2022; (63(10)):2383-2392 doi:10.1080/10428194.2022.2076847.

    PMID: 35730586
  24. 24

    Risk stratification in multiple myeloma: Are we there yet?

    Mohan M, Schinke C

    British journal of haematology 2024; (204(5)):1585-1587 doi:10.1111/bjh.19416.

    PMID: 38616560

This page provides general information about standard treatments for AL amyloidosis. Always consult your hematologist or oncologist for personalized medical advice regarding your specific treatment plan and eligibility for procedures.

Get notified when new evidence is published on AL amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.